Martine Piccart

Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).

M. Piccart, K. Mcgregor, R. Stahel, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunotherapy for early breast cancer: too soon, too superficial, or just right?

M. Piccart, E. Romano, M. Franzoi, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes

M. Piccart, Z. Aziz, D. Fraser, 2017, The Pharmacogenomics Journal.

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

S. Loi, V. Nekljudova, C. Schem, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.

C. Criscitiello, S. Cosimo, E. Azambuja, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.